Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1 (AcSé)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02034981
Recruitment Status : Active, not recruiting
First Posted : January 14, 2014
Last Update Posted : March 25, 2021
Sponsor:
Collaborators:
National Cancer Institute, France
Fondation ARC
Pfizer
Information provided by (Responsible Party):
UNICANCER